<DOC>
	<DOC>NCT01412944</DOC>
	<brief_summary>The study will assess the safety and efficacy of intravenous (10mg/kg) and subcutaneous (300mg) secukinumab in moderate to severe chronic plaque-type psoriasis who are partial responders to secukinumab.</brief_summary>
	<brief_title>Efficacy and Safety of Intravenous and Subcutaneous Secukinumab in Moderate to Severe Chronic Plaque-type Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Inclusion criteria: Written Informed Consent must be obtained before any assessment is performed, Subject must be able to understand and communicate with the investigator and comply with the requirements of the study. Subjects must have participated in the study CAIN457A2304 and have achieved a partial response after twelve weeks of treatment with no major protocol deviations. A partial response is defined as having achieved â‰¥ PASI 50 but &lt; 75 response. Exclusion criteria Pregnant women or lactating women Forms of psoriasis other than chronic plaque type Ongoing use of prohibited psoriasis treatments Ongoing use of other nonpsoriasis prohibited treatments Previous exposure to any biologic drug directly targeting IL17 or the IL17 receptor, except secukinumab in study CAIN457A2304 Active ongoing inflammation diseases other than psoriasis that might confound the evaluation of the benefits of secukinumab therapy UV therapy or excessive exposure to sunlight</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Psoriasis</keyword>
	<keyword>plaque</keyword>
	<keyword>inflammatory skin disease</keyword>
	<keyword>scaly patches</keyword>
	<keyword>AIN457</keyword>
	<keyword>secukinumab</keyword>
	<keyword>Moderate to severe</keyword>
</DOC>